This discussion guide is intended to help optimize SGLT2 inhibitor use to prevent adverse cardiovascular events and improve outcomes in patients with heart failure, diabetes and chronic kidney disease.
Use it to start conversations about the role of SGLT2 inhibitors – in reducing cardiovascular events and declines in kidney function and extending survival – and ensure timely initiation of therapy in appropriate populations.